Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Kritika Sarmah

Gilead Sciences’ Quarterly Earnings Preview: What You Need to Know

Gilead Sciences, Inc. (GILD), headquartered in Foster City, California, is a global biopharmaceutical leader known for its groundbreaking work in antiviral therapies. Valued at a market cap of $108 billion, Gilead's innovative portfolio delivers cutting-edge treatments that improve patient outcomes in areas such as HIV, hepatitis, and cancer. The company is set to announce its fiscal Q3 earnings results after the market closes on Wednesday, November 6.

Ahead of the event, analysts expect GILD to report a profit of $1.64 per share, down 28.4% from $2.29 per share in the year-ago quarter. The company surpassed Wall Street’s bottom-line estimates in three quarters and missed on another occasion in the last four quarters.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.